Provectus Biopharmaceuticals Inc (PVCT)

[crudeoil24]

<<< NEWS >>> Provectus Biopharmaceuticals Announces Acceptance of Abstract for Poster Presentation at 31(st) SITC Annual Meeting
3 hours 17 minutes ago - DJNF
Poster Presentation of Data on PV-10 in Treatment of Pancreatic Cancer Accepted
Conference Scheduled for November 9-13, 2016 in National Harbor, Maryland

KNOXVILLE, Tenn.--(BUSINESS WIRE)--September 27, 2016--

Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), today announced that the Society for Immunotherapy of Cancer has accepted an abstract for a poster presentation related to the use of PV-10, an investigational ablative immunotherapy under development by Provectus for solid tumor cancers, in the treatment of pancreatic cancer.

The abstract, "Intralesional injection with Rose Bengal and systemic chemotherapy induces anti-tumor immunity in a murine model of pancreatic cancer," describes research undertaken at Moffitt Cancer Center by a team of scientists led by Shari Pilon-Thomas. The exact time and place of the poster presentation has yet to be determined. The full abstract will be available on line at SITCancer.org on November 8 according to conference organizers.

The 31(st) SITC Annual Meeting and Associated Programs will be held November 9-13 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to professionals working in the field of cancer immunology and immunotherapy. Established in 1984, SITC is a 501(c)(3) not-for-profit organization with a growing constituency of academic, government, industry, clinical and basic scientists, and practitioners from around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.